MRVI Maravai Lifesciences Holdings Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: MRVI

Price (delayed)

$4.99

Market cap

$1.29B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$0.71

Enterprise value

$1.39B

?
Relative Growth: Rel. Growth: 40
Relative Strength: Rel. Strength: 89
Relative Valuation: Rel. Valuation: 15
Relative Profitability: Rel. Profitability: 25

Maravai LifeSciences enables the development of drug therapies, diagnostics and novel vaccines and supports research on human diseases through its portfolio of market-leading companies and proprietary technologies. Maravai companies are ...

Highlights
Maravai Lifesciences Holdings's EPS has increased by 38% YoY and by 21% from the previous quarter
MRVI's net income is up by 36% year-on-year and by 20% since the previous quarter
Maravai Lifesciences Holdings's gross profit has surged by 76% QoQ but it has decreased by 34% YoY
Maravai Lifesciences Holdings's gross margin has surged by 60% QoQ but it has decreased by 21% YoY
The company's equity fell by 30% YoY
Maravai Lifesciences Holdings's quick ratio has decreased by 13% QoQ and by 6% YoY
Sector: Healthcare
Industry: Biotechnology
Website: http://www.maravai.com
Peers: NVAX NVCR NBIX

Key stats

What are the main financial stats of MRVI

MRVI stock price

How has the Maravai Lifesciences Holdings stock price performed over time
Intraday
3.1%
1 week
7.54%
1 month
31.66%
1 year
125.79%
YTD
53.54%
QTD
76.33%

Financial performance

How have Maravai Lifesciences Holdings's revenue and profit performed over time
Revenue
$204.73M
Gross profit
$59.97M
Operating income
-$168.06M
Net income
-$104.56M
Gross margin
29.3%
Net margin
-51.1%
Maravai Lifesciences Holdings's gross profit has surged by 76% QoQ but it has decreased by 34% YoY
Maravai Lifesciences Holdings's gross margin has surged by 60% QoQ but it has decreased by 21% YoY
The operating income is up by 37% year-on-year and by 22% since the previous quarter
MRVI's net income is up by 36% year-on-year and by 20% since the previous quarter

Price vs fundamentals

How does MRVI's price correlate with its fundamentals

Growth

What is Maravai Lifesciences Holdings's growth rate over time

Valuation

What is Maravai Lifesciences Holdings stock price valuation
MRVI P/E details
P/E
N/A
P/B
6.06
P/S
3.57
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
6.81
Maravai Lifesciences Holdings's EPS has increased by 38% YoY and by 21% from the previous quarter
MRVI's price to book (P/B) is 84% more than its last 4 quarters average of 3.2 but 52% less than its 5-year quarterly average of 12.3
The company's equity fell by 30% YoY
The price to sales (P/S) is 65% more than the last 4 quarters average of 2.1 but 6% less than the 5-year quarterly average of 3.7
Maravai Lifesciences Holdings's revenue has decreased by 15% YoY but it has increased by 10% from the previous quarter

Efficiency

How efficient is Maravai Lifesciences Holdings business performance
Maravai Lifesciences Holdings's ROS has increased by 30% from the previous quarter and by 19% YoY
The company's return on invested capital rose by 20% QoQ and by 10% YoY
The return on assets has grown by 14% since the previous quarter and by 7% year-on-year
The return on equity is up by 13% since the previous quarter and by 3.2% year-on-year

Dividends

What is MRVI's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for MRVI.

Financial health

How did Maravai Lifesciences Holdings financials performed over time
MRVI's total assets is 107% greater than its total liabilities
MRVI's total assets is down by 26% year-on-year and by 7% since the previous quarter
The total liabilities has decreased by 20% YoY and by 14% from the previous quarter
The company's debt is 28% higher than its equity
The company's equity fell by 30% YoY
The company's debt fell by 17% YoY and by 16% QoQ

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.